Reuters logo
BRIEF-Ablynx's anti-vWF nanobody, caplacizumab, achieves clinical proof-of-concept in phase II titan study
June 17, 2014 / 5:12 AM / 3 years ago

BRIEF-Ablynx's anti-vWF nanobody, caplacizumab, achieves clinical proof-of-concept in phase II titan study

June 17 (Reuters) - Ablynx Nv

* Ablynx’s anti-vwf nanobody, caplacizumab, achieves clinical proof-of-concept in phase ii titan study

* First-in-class potential with orphan drug status for treatment of acquired thrombotic thrombocytopenic purpura

* Proof-of-concept with statistically significant 39% decrease in time to normalisation of platelet count compared to placebo for patients Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below